Overview

Study of Efficacy and Safety of Inclisiran in Japanese Participants With High Cardiovascular Risk and Elevated LDL-C

Status:
Active, not recruiting
Trial end date:
2022-12-23
Target enrollment:
Participant gender:
Summary
The aim of the study is to assess the efficacy and safety of inclisiran in Japanese participants with an increased LDL-C concentrations. The study also evaluates the pharmacokinetics of inclisiran in a subset of Japanese participants.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals